Perpetual Ltd Purchases 9,261 Shares of Merck & Co., Inc. $MRK

Key Points

• Perpetual Ltd increased its stake in Merck by 1.7%, buying 9,261 shares and now owns 563,716 shares valued at about $59.34 million; institutional investors hold roughly 76.07% of MRK.
• Merck has several near‑term growth catalysts — including an EU approval expanding KEYTRUDA use, a pivotal trial for MK‑8748 in wet AMD, and positive Phase 3 data for an oral PCSK9 — and analysts collectively rate MRK a “Moderate Buy” with an average target of $127.13.
• Insider selling has been notable (CEO sold 47,434 shares; insiders sold 320,176 shares in the last 90 days), while Merck beat quarterly EPS estimates, set FY2026 guidance of $5.00–$5.15, and announced a $0.85 quarterly dividend (2.8% yield).

Perpetual Ltd boosted its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 1.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 563,716 shares of the company's stock after acquiring an additional 9,261 shares during the quarter. Perpetual Ltd's holdings in Merck & Co., Inc. were worth $59,337,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of MRK. Darwin Wealth Management LLC grew its stake in shares of Merck & Co., Inc. by 237.4% during the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company's stock valued at $26,000 after purchasing an additional 216 shares during the period. Kilter Group LLC bought a new position in shares of Merck & Co., Inc. in the 2nd quarter worth approximately $27,000. Barnes Dennig Private Wealth Management LLC lifted its stake in shares of Merck & Co., Inc. by 302.3% in the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company's stock worth $30,000 after purchasing an additional 266 shares during the period. United Financial Planning Group LLC purchased a new position in shares of Merck & Co., Inc. in the third quarter worth approximately $31,000. Finally, Evolution Wealth Management Inc. purchased a new position in shares of Merck & Co., Inc. in the second quarter worth approximately $31,000. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: EU approval expands KEYTRUDA use to PD‑L1 positive, platinum‑resistant ovarian cancer — opens a new commercial indication in Europe for an established franchise, which can drive incremental revenue and utilization in a high‑unmet‑need setting. Merck Broadens Cancer And Eye Disease Pipeline As Investors Weigh Future Growth
• Positive Sentiment: Merck initiated a pivotal Phase 2b/3 trial of MK‑8748 (Tiespectus) for wet AMD — a promising ophthalmology program that, if successful, adds a non‑oncology growth vector and diversifies long‑term revenue streams. Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus)
• Positive Sentiment: Positive Phase 3 CORALreef results for oral PCSK9 inhibitor (enlicitide decanoate) — if approved, an oral PCSK9 could be a major commercial opportunity in cardiovascular prevention and complement existing lipid therapies. Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Detailed Phase 2 CADENCE data for WINREVAIR released — adds evidence to a respiratory program that management can highlight to investors as part of a broader R&D pipeline story. Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck KGaA acquisition of JSR chromatography business noted in the press — this concerns Merck KGaA (a different company) and is unlikely to meaningfully affect Merck & Co.’s (MRK) near‑term fundamentals. Merck KGaA acquires JSR chromatography
• Negative Sentiment: New proposal from former President Trump to impose up to 100% tariffs on imported medicines (with carve‑outs) increases regulatory and pricing uncertainty for the sector; even with exemptions, the proposal raises near‑term headline risk and could pressure sentiment toward large pharma names like MRK until policy clarity emerges. Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions
• Negative Sentiment: Sector policy debate over drug‑pricing deals continues (Lilly warns against locking pricing deals into law) — ongoing political scrutiny increases the chance of policy actions that could cap pricing or change reimbursement, a headwind for long‑term margin visibility. Lilly Pushes Back on Making Drug Price Deals Permanent

Analyst Upgrades and Downgrades

A number of analysts have commented on MRK shares. Wall Street Zen raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a report on Saturday, March 28th. Royal Bank Of Canada reiterated an "outperform" rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Zacks Research raised shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 17th. Wolfe Research upgraded Merck & Co., Inc. from a "peer perform" rating to an "outperform" rating and set a $135.00 price objective for the company in a research note on Thursday, January 8th. Finally, Barclays began coverage on Merck & Co., Inc. in a report on Friday, February 20th. They issued an "overweight" rating and a $140.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $127.13.

Insider Activity at Merck & Co., Inc.

In related news, CEO Robert M. Davis sold 47,434 shares of the company's stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $118.04, for a total value of $5,599,109.36. Following the completion of the transaction, the chief executive officer owned 443,602 shares of the company's stock, valued at approximately $52,362,780.08. This represents a 9.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CMO Chirfi Guindo sold 20,000 shares of the company's stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the completion of the transaction, the chief marketing officer directly owned 80,615 shares of the company's stock, valued at $9,825,356.20. This represents a 19.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 320,176 shares of company stock worth $38,281,735 in the last 90 days. Company insiders own 0.13% of the company's stock.

Merck & Co., Inc. Trading Down 0.2%

Merck & Co., Inc. stock opened at $120.62 on Friday. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The firm has a market capitalization of $298.21 billion, a price-to-earnings ratio of 16.57, a P/E/G ratio of 2.44 and a beta of 0.26. The firm has a 50 day moving average of $117.72 and a 200 day moving average of $103.08. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.03. The business had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be paid a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. Merck & Co., Inc.'s payout ratio is 46.70%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.